Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients
NCT04581967
·
clinicaltrials.gov ↗
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer Patients
Interventions
GENETIC:
polymorphism analysis
DRUG:
Doxorubicin-Cyclophosphamide regimen
Sponsor
Damanhour University
Collaborators
[object Object]
[object Object]